{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-055999","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.925095+00:00","generated_at":"2026-06-15T21:36:59.944299+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cognition Therapeutics Q1 net loss $6.2M; advances Alzheimer's and dry AMD trials","bullets":["Net loss $6.2M ($0.21 per share) vs $3.8M ($0.17) in Q1 2022.","Cash $38.8M; runway into H2 2024; $35M equity agreement with Lincoln Park Capital.","Completed enrollment in Phase 2 SEQUEL (Alzheimer's); topline data expected Q2 2023.","FDA cleared Phase 2 START (540 patients) for early AD and Phase 2 MAGNIFY for dry AMD.","Hired John Doyle as CFO effective May 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-055999","json":"https://secwatch.observer/filing/0001104659-23-055999.json","markdown":"https://secwatch.observer/filing/0001104659-23-055999.md","text":"https://secwatch.observer/filing/0001104659-23-055999.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923055999/0001104659-23-055999-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923055999/tm2314531d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:36:59.944299+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b94e265f0b928c3f53b999d9b2c2be4205787e8a","claim":"COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2023 results: net income a net loss of $6.2 million, EPS $(0.21) per basic and diluted share.","evidence_excerpt":"The Company reported a net loss of $6.2 million, or $(0.21) per basic and diluted share for the first quarter ended March 31, 2023, compared to a net loss of $3.8 million or $(0.17) per basic and diluted share during the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1455365/000110465923055999/0001104659-23-055999-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Net income","value":"a net loss of $6.2 million"},{"label":"EPS","value":"$(0.21) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}